Iryna Drozd Lexicon Pharmaceuticals ( NASDAQ: LXRX ) said the FDA has declined to approve its drug Zynquista, also known as sotagliflozin, as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and chronic kidney disease, or CKD, issuing the company a Complete.
Back to Health Page
:upscale()/2024/04/23/894/n/1922729/tmp_vSUGEq_06cf7e5f3134ead7_Main_PS24_ConditionCenter_Crohn_sDisease.jpg)
